Andrew Kaiser

USPTO Granted Patents = 11 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 71(Granted Patents)

Location History:

Rosrath, DE (2018 - 2024)
Bergisch Gladbach, DE (2019 - 2024)

Company Filing History:

8 out of 41

Miltenyi Biotec B.v. Co., Kg

patents

2 out of 58

Miltenyi Biotec, Gmbh

patents

1 out of 1

Miltenyi Biorec B V. Co., Kg

patent

4. 1 out of 49

Charité – Universitätsmedizin Berlin

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365916 - Adapter-based retroviral vector system for the selective transduction of target cells (2025-07-22),

2. 12318446 - Reducing side effects of immunotherapy using genetically modified hematopoietic cells (2025-06-03),

3. 12246065 - Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen (2025-03-11),

4. 12178872 - Regulatory T cell expressing a chimeric antigen receptor (2024-12-31),

5. 12018273 - CD62L specific lentiviral vector particle for targeted transduction of T cell subsets (2024-06-25),

6. 11890300 - Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor (2024-02-06),

7. 11883494 - Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form (2024-01-30),

8. 11419935 - Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells (2022-08-23),

9. 11033619 - Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form (2021-06-15),

10. 10201606 - Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases (2019-02-12),

11. 10131876 - Method for automated generation of genetically modified T cells (2018-11-20),

Title: Andrew Kaiser: Innovator in Retroviral Vector Systems and Immunotherapy

Introduction

Andrew Kaiser is a prominent inventor based in Bergisch Gladbach, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of innovative systems for gene therapy and immunotherapy. With a total of 11 patents to his name, his work has the potential to transform therapeutic approaches in medicine.

Latest Patents

One of Andrew Kaiser's latest patents is an "Adapter-based retroviral vector system for the selective transduction of target cells." This invention provides a composition that includes a pseudotyped retroviral vector particle designed to selectively transduce target cells. The system utilizes envelope proteins with antigen-binding activity, allowing for targeted delivery of therapeutic agents to specific cells. Another notable patent focuses on "Reducing side effects of immunotherapy using genetically modified hematopoietic cells." This disclosure presents a method to prevent or reduce side effects in patients undergoing immunotherapy, such as CAR T cell therapy, by using engineered hematopoietic cells that either do not express the target antigen or express it in a modified form.

Career Highlights

Throughout his career, Andrew Kaiser has worked with notable companies in the biotechnology sector, including Miltenyi Biotec B.V. & Co. KG and Miltenyi Biotec, GmbH. His expertise in developing advanced therapeutic systems has positioned him as a key figure in the industry.

Collaborations

Andrew has collaborated with esteemed colleagues, including Mario Assenmacher and Michael Lutteropp, contributing to the advancement of innovative solutions in biotechnology.

Conclusion

Andrew Kaiser is a distinguished inventor whose work in retroviral vector systems and immunotherapy is paving the way for new therapeutic strategies. His contributions are vital to the ongoing evolution of medical treatments, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.